The Effect of Saquinavir on the Rate of Metabolism of Midazolam
Abstract
Midazolam (MDZ) is used extensively for sedation by clinicians including anesthesia providers. There have been reports that its effects have been enhanced in the presence of other drugs with negative patient outcomes. The P450 mixed function oxidase system contains an enzyme subfamily known as CYP3A. These enzymes have been identified as primarily responsible for the metabolism of MDZ. Protease inhibitors such as saquinavir may inhibit some P450 isoforms. The metabolism of MDZ in the presence of protease inhibitors is presently unclear. This study examines the effect of saquinavir on the rate of metabolism of MDZ. Human liver microsomes were incubated with MDZ with and without saquinavir.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1999
- Accession Number
- AD1012251
Entities
People
- Brian G. Todd
Organizations
- Uniformed Services University of the Health Sciences